Phase I – First Administration to Humans

783 trials 323 recruiting

Filter these 783 trials by condition, country, sponsor and more.

Open in Search →

A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relaps… Ended

2024-515582-33-00 Relapsed/Refractory Multiple Myeloma (RRMM) 2020-10-26
A Phase 1 Study of JNJ-70218902, a T Cell Redirecting Agent, in Advanced Stage Solid Tumors Ended

2024-516351-40-00 Metastatic Castration-Resistant Prostate Cancer 2020-07-15
Dose-Escalation Study of Cevostamab in Participants with Relapsed or Refractory Multiple Myeloma Ended

2022-502053-34-00 Multiple Myeloma (MM) 2020-07-13
A Phase I, First In Human, open-label study of escalating doses of INA03 administered intravenously as single agent in adult patients with r… Ended

2024-518265-10-01 Relapse/ refractory acute Leukemia 2020-06-03
A phase 1/2a study to evaluate the dose, safety, tolerability, and efficacy of an intraperitoneal α-emitting radionuclide therapy (Radspheri… Ended

2024-511853-23-00 Peritoneal carcinomatosis (PC) from colorectal carcinom 2020-05-12
A Study to Evaluate Safety and Anti-Tumor Activity of RO7284755 Alone or in Combination with Atezolizumab in Participants with Advanced and/… Ended

2023-503749-76-00 Solid Tumors 2020-03-06
Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies Ended

2024-515827-12-00 Acute Myeloid Leukemia (AML) 2020-01-28
A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in… Ended

2024-512734-15-00 Non-Hodgkin lymphoma and chronic lymphocytic leukemia 2019-10-23
A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced S… Ended

2024-513574-21-00 Neoplasms 2019-08-09
A phase 1 study of oral Debio 0123 in combination with carboplatin in patients with advanced solid tumors Ended

2024-510984-52-00 Patients with tumors 2019-05-24
A study to investigate the safety, the amount that reaches the bloodstream and the effects on the body of JNJ-64619178 in people with advanc… Ended

2024-515254-24-00 Previously treated lymphoma (blood cancer) or solid tum 2018-11-08
A Study to Evaluate Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination with Atezolizumab in Patients with Locally… Ended

2023-504224-26-00 Advanced tumors 2018-07-03
A Trial to Determine the Safety of CC-93269, an Antibody, in People who have Multiple Myeloma That Has Returned After a Period of Treatment … Ended

2023-506564-14-00 Relapsed and refractory multiple myeloma (RRMM) 2018-05-16
A study to assess the safety and anti-tumor activity of T cell therapy in subjects with advanced liver cancer or any other AFP expressing tu… Ended

2024-514437-37-00 Advanced Hepatocellular Carcinoma (HCC) that is not ame 2018-02-22
This is clinical study to test, for the first time in people, the safety (any good or bad effects), how long the drug can stay in the body a… Ended

2023-509969-20-00 Part C: advanced or unresectable STs (Spain only) 2017-07-24
A phase I dose finding study of oral TNO155 in adult patients with advanced solid tumors Ended

2023-508925-29-00 Advanced solid tumors 2017-06-29
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MD… Ended

2023-507154-32-00 Myelodysplastic Syndromes (MDS) 2017-02-17
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies Ended

2024-514938-20-00 B-cell non-Hodgkin lymphoma (NHL) 2016-08-31
Treatment of neuroendocrine neoplasms with genetically modified adenovirus Ended

2024-517654-10-00 Neuroendocrine neoplasms (NENs) is a heterogeneous grou 2016-03-15
Study is designed to assess the safety and tolerability of ceralasertib at increasing doses in combination with other anti-cancer treatment … Ended

2023-505006-41-00 QT interval prolongation 2015-05-11
A Phase 1 study to evaluate IK-930 in subjects with advanced solid tumors Ended

2022-502622-40-00 Advanced Solid Tumors
European, multicentre, single arm (phase I) trial of autologous skeletal muscle derived cell (ASMDC) microcarrier combination for the treatm… Ended

2023-504282-23-00 Faecal incontinence
A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers Ended

2023-507674-41-00 Advanced high-grade serous ovarian cancer (OC)
NXP800 in subjects with Ovarian Cancer Ended

2023-509150-64-00 Platinum-resistant, ARID1a-mutated ovarian, fallopian t